The latest price target for Neumora Therapeutics (NASDAQ:NMRA) was reported by RBC Capital on December 1, 2025. The analyst firm set a price target for $7.00 expecting NMRA to rise to within 12 months (a possible 255.33% upside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Neumora Therapeutics (NASDAQ:NMRA) was provided by RBC Capital, and Neumora Therapeutics upgraded their outperform rating.

The last upgrade for Neumora Therapeutics Inc happened on December 1, 2025 when RBC Capital raised their price target to $7. RBC Capital previously had a sector perform for Neumora Therapeutics Inc.

The last downgrade for Neumora Therapeutics Inc happened on September 16, 2025 when JP Morgan changed their price target from N/A to N/A for Neumora Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neumora Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neumora Therapeutics was filed on December 1, 2025 so you should expect the next rating to be made available sometime around December 1, 2026.

While ratings are subjective and will change, the latest Neumora Therapeutics (NMRA) rating was a upgraded with a price target of $4.00 to $7.00. The current price Neumora Therapeutics (NMRA) is trading at is $1.97, which is out of the analyst’s predicted range.